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Enriching Traditional Protein-
protein Interaction Networks with 
Alternative Conformations of 
Proteins
Farideh Halakou1, Emel Sen Kilic  2,4, Engin Cukuroglu3, Ozlem Keskin2 & Attila Gursoy1
Traditional Protein-Protein Interaction (PPI) networks, which use a node and edge representation, 
lack some valuable information about the mechanistic details of biological processes. Mapping protein 
structures to these PPI networks not only provides structural details of each interaction but also helps 
us to find the mutual exclusive interactions. Yet it is not a comprehensive representation as it neglects 
the conformational changes of proteins which may lead to different interactions, functions, and 
downstream signalling. In this study, we proposed a new representation for structural PPI networks 
inspecting the alternative conformations of proteins. We performed a large-scale study by creating 
breast cancer metastasis network and equipped it with different conformers of proteins. Our results 
showed that although 88% of proteins in our network has at least two structures in Protein Data Bank 
(PDB), only 22% of them have alternative conformations and the remaining proteins have different 
regions saved in PDB. However, using even this small set of alternative conformations we observed a 
considerable increase in our protein docking predictions. Our protein-protein interaction predictions 
increased from 54% to 76% using the alternative conformations. We also showed the benefits of 
investigating structural data and alternative conformations of proteins through three case studies.
The most common representation of PPI networks is a graph demonstration. In these PPI graphs, nodes repre-
sent the proteins and edges represent their interactions. This abstract representation provides a global picture of 
biological processes and protein function and helps us to simplify complex cellular systems1. However, to deeply 
understand functional roles and binding mechanisms of proteins, we need to include an extra piece of informa-
tion in these PPI networks which comes from structural data.
Addition of the structural information to the traditional PPI networks enables us to answer some essential 
questions in systems biology: (A) The first question would be, how is it possible for some proteins to have tens 
and even hundreds of interactions in PPI networks? Since proteins have a limited surface area, a single protein 
cannot interact with such a large number of partners at the same time. Tsai et al.2 show that the problem arises 
from the traditional representation of PPI networks. In these networks, all the protein products of a single gene 
are mapped into a single node. So, in protein interaction networks, each node represents a collection of proteins, 
each with a distinct conformation or spliced form. Even though the conformations are not totally different, the 
small differences suffice to bring new interactions. Nevertheless, the number of interactions can vary from one 
protein to another. Structural analysis suggests that the essential proteins in the PPI networks have more binding 
sites than other proteins3. On the other hand, it has been shown that the larger the number of partners a hub pro-
tein has, the higher the probability of the hub essentiality is4. (B) The next question would be, which interactions 
can occur simultaneously and which are mutually excluded? To answer this question, we need to investigate a new 
dimension in PPI networks which is time5. One of the first pioneering works in this field was done by Kim et al.6. 
They mapped the protein interactions to known interface structures by using their sequence similarity. They 
identified mutually exclusive interactions by inspecting the usage of the same binding interface on their structural 
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yeast interaction network. Similar to this study, Tuncbag et al.5 used p53 pathway as a case study and predicted 
the simultaneous and mutually exclusive interactions in their network. Kuzu et al.7 used structural interaction 
networks to find simultaneous and mutually exclusive interactions on ERK and MAPK pathways. C) Another 
question would be, how can mutations, located on interfaces, surfaces, or buried in the core regions of proteins, 
affect the PPI networks? It has been shown that mutations located on interaction interfaces of a protein are more 
likely causing distinct interruptions in the overall interactome8. Therefore, they can result in different biologi-
cal phenotypes. In a recent study, Mosca et al.9 created a resource named dSysMap which systematically maps 
disease-related missense mutations on the structurally annotated human interactome. Their study shows that if 
pairs of mutations are located in different interfaces of the same protein, they usually cause different phenotypes. 
However, if they are located in the same interface of interacting proteins, they are most likely producing the same 
phenotype. To predict the effects of mutations on PPI networks, Moretti et al.10 performed a community-wide 
assessment of available methods. They computationally designed influenza binders HB36.4 and HB80.3, and then 
created single point mutant variants corresponding to all 20 amino acids at each position of the binders. They 
showed that mutations can influence binding if they disrupt the folded state.
The common practice in structural PPI networks is to inspect just one protein structure for each node. 
However, proteins are flexible11, 12 and their conformations change based on the factors like post-translational 
modifications, pH level, and environment. Thus, we need to consider an ensemble of protein conformers for 
each node in PPI networks. The conformational changes dictate the protein function. Therefore, characteriza-
tion of this association between protein conformation and its function, helps us to understand how to alter and 
regulate protein activity. The importance of investigating multiple conformers of the proteins in PPI networks 
lies in the fact that protein conformational changes cause activation of specific pathways13–15. A proper exam-
ple could be RAS-family proteins. RAS proteins switch between GDP-bound inactive form to the GTP-bound 
active form, as two conformational states, in response to receptor-mediated extracellular signals16. They regu-
late proliferation, differentiation, motility and cytoskeletal re-organization17, 18. The conversion of GTP-bound to 
GDP-bound form is regulated by guanine nucleotide exchange factors (GEFs), and the conversion of GDP-bound 
to GTP-bound form is mediated by GTPase activating proteins (GAPs)19. Active RAS interacts with its effec-
tor proteins and activates downstream effectors like Raf kinase, phosphatidylinositol 3-kinase and Ral guanine 
nucleotide-dissociation stimulator20. Schematic representation of RAS conformational states and their corre-
sponding interactions are shown in Fig. 1.
RAS example intensifies the investigation of different conformers of proteins in structural PPI networks. 
Protein Data Bank (PDB)21 provides protein structures which include alternative conformations of the same 
protein coming from different experiments. Kuzu et al.22 used an ensemble of protein conformations to dock 
the difficult cases of a docking benchmark data set. Applying the alternative conformations of proteins signifi-
cantly increased the probability of successful protein interaction prediction in their study. They created the net-
work of ERK interactions as a case study. Also, ensemble of protein conformations are used in docking to model 
small-molecule-protein or peptide-protein interactions23, 24. However, ensemble docking studies are neither at 
network level, nor for protein interactions, they usually make use of computationally generated conformations 
rather than multiple conformations obtained from PDB.
There are some recent databases which explore the conformational changes and flexibility of protein struc-
tures deposited in PDB database such as CCProf25, PDBFlex26, and CoDNaS 2.027. PDBFlex database provides 
the analysis of structural variations between the different depositions for the same protein in the PDB database. 
It clusters different structures of proteins based on their sequence similarity and animates its dynamics. CCProf 
database also offers conformational changes of protein structures plus some other beneficial biological features 
like potential binding target site, secondary structure, conservation, phosphorylation site and catalytic site. 
CoDNaS database covers a large proportion of available protein structures derived from X-ray crystallography 
Figure 1. Schematic representation of RAS protein conformational states. In the active form, RAS can bind to 
its effectors and activate different signalling pathways.
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and NMR experiments in the PDB database. It clusters the protein structures using their sequence identity too. 
There are ~15 conformers on average for each protein chain in this database.
In this study, we concentrate on mapping structural data into the PPI networks and investigating alterna-
tive conformations of these protein structures. We have chosen the breast cancer lung and brain metastasis PPI 
networks of our previous study28. After creating the traditional PPI network of breast cancer lung and brain 
metastasis, we enriched them by alternative conformations of the proteins. This new enriched network helps us to 
understand how proteins interact with each other using specific conformations and how these alternative confor-
mations lead to diverse downstream signalling. It also shows us the effects of mutations on protein conformation, 
its interaction and function.
Materials and Methods
To have a more realistic view of PPI networks, we propose a new PPI representation as in Fig. 2. This representa-
tion covers proteins’ alternative conformations and shows their specific interactions with their binding partners. 
In this representation, each protein p in the network is an ensemble of that proteins states/conformations {pc1, pc2, 
… pcn} which can inter-convert to each other. If p1 and p2 have N and M alternative conformations respectively, 
the edge {p1, p2} shows that at least one {p1ci, p2cj} i ≤ N, j ≤ M is physicochemically possible. This new rep-
resentation reveals two important facts about PPI networks. First, each specific protein conformer can contribute 
to a number of potential interactions the protein can have. In Fig. 2, for example, if p3 is in conformation 2 (p3c2), 
it can only bind to p4 if p4 is in its c2 or c3 conformations. However, if p3 is in conformation c3, it may bind to 
p1, p2, or p3. Second, each edge in the PPI network has a strength based on the present conformations of the 
proteins in the network at any time point. Namely, some edges can be formed more probably as the correspond-
ing interacting proteins can bind to each other using different conformations. For example, edge {p3, p5} can be 
speculated to be less probable than {p3, p4}, as the latter can happen regardless of which conformation p3 has.
To create the multi-conformational PPI network, we followed the steps shown in Fig. 3. The process starts with 
creating a traditional PPI network for the phenotype of interest. In this network, nodes show the proteins and 
edges show the protein-protein interactions. Afterwards, available PDB structures of each protein in the network 
are mapped to it. Protein structures are all stored in PDB database21. As it is a redundant database, mapping all 
of the structures without any curation can cause unnecessary repetition in the 3D protein-protein interaction 
predictions. Thus, similar PDB structures which correspond to the same protein should be eliminated. For each 
protein, we cluster its alternative conformations according to their sequence and structural similarities. Then, the 
possible protein-protein interactions using each specific protein conformation are investigated using a docking 
method. We use PRISM in this study for interaction prediction because unlike many docking methods designed 
just for a binary interaction, PRISM is able to get a PPI network as an input which makes it suitable for large scale 
studies. The graphical illustration of the multi-conformational PPI network creation procedure is illustrated in 
Fig. 4.
After clustering the protein structures according to their similarities, one or more structures remain as their 
clusters’ representatives for each protein. To predict if two connected proteins in the network can bind to each 
other or not, we explored all permutations of their representative structures. As we can see in the results section, 
some interactions in the network are feasible only by using specific conformations of the interacting proteins. This 
fact may change the topology of the network at each specific time point as each protein can form different inter-
actions based on its conformation in the network. This is one of the major points that traditional PPI networks 
are not able to show.
Figure 2. Structural PPI network in traditional representation on the left, and the new representation 
investigating proteins conformational changes on the right. Arrows show inter-conversions between alternative 
conformations of the same protein.
www.nature.com/scientificreports/
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Clustering PDB Structures to Form Alternative Conformations. We cluster protein structures using 
their sequence identity and structural similarity, and choose a representative structure for each cluster represent-
ing an alternative conformation of the same protein in our network. First, we use UniProt Knowledgebase29 to 
map proteins to their known 3D structures which provides a list of corresponding available structures in PDB. In 
this step, protein structures which have less than 30 residues are eliminated. Secondly, all available structures for 
each UniProt ID are structurally aligned using TMAlign tool30 to each other to quantify their structural differ-
ences. In order to find the unique protein structures, we use agglomerative complete linkage clustering method 
based on sequence similarity and RMSD value of the protein structures. If two protein structures, corresponding 
to the same UniProt ID, have more than 95% sequence identity and smaller than 2 Å RMSD value, we put them 
together in a cluster. We applied this procedure until there is not any protein structures left without an assigned 
cluster information. Representative structures for each cluster are selected based on the best intra-cluster simi-
larity and RMSD value. These representative structures are the alternative structures of a node corresponding to 
a protein in our merged structural network (Supplementary Data 3). We should note that it is possible that some 
clusters represent different parts of the same protein because PDB structures do not necessarily cover the com-
plete protein sequence. Since they all correspond to different parts of the protein, they still will contribute to some 
specific interactions in the PPI network. Therefore, we keep all representatives in the network.
Creating Breast Cancer Metastases Network. Advances in systems biology over the past years have 
provided a large amount of experimental high-throughput data on protein interactions. This information is 
spread across multiple databases with some overlap. In addition, given the variations in the experimental tech-
niques used, each database has a different level of reliability for its data. Therefore, a tool is required to unify these 
data independently of the identifiers used in each database. We constructed the PPI network for breast cancer 
lung and brain metastasis by using GUILDify webserver31. This webserver uses BIANA32 to construct the network 
and scores the nodes by using GUILD33, which is based on network-based prioritization algorithms. GUILDify 
Figure 3. Flowchart of creating the multi-conformational PPI network.
Figure 4. Graphical illustration of creating the multi-conformational PPI network. (a) Traditional PPI network. 
Each node represents a protein. (b) Available PDB structures for each protein. Similar conformations for each 
protein, indicated with the same colour, are clustered together. (c) For each cluster, just one PDB structure is 
selected as its representative. Two proteins may bind to each other by using specific conformations.
www.nature.com/scientificreports/
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webserver first maps the seed genes, which are previously known to be associated with a specific phenotype, into 
a genome wide human interaction network provided by BIANA and scores other genes based on their association 
with the seed genes by using a combination of network-based parameters i.e. NetScore, NetZscore and NetShort32.
We made use of the genes identified by Minn et al.34 and Bos et al.35 as seed genes, which were also used previ-
ously by Engin et al.36 as well, to generate lung and brain metastasis subnetworks of breast cancer. They identified 
18 genes mediating breast cancer to lung metastasis and 17 genes mediating breast cancer to brain metastasis. 
Supplementary Table S1 shows the seed genes used. GUILDify scores genes based on their associations with 
brain and lung metastasis phenotypes. Thus, each node (gene) has two separate scores which lead to two different 
subnetworks namely BMSN (Brain Metastasis SubNetwork) and LMSN (Lung Metastasis SubNetwork). BMSN 
and LMSN can be found in Supplementary Data 1 and 2 files. The GUILDify scores were presented only for the 
genes but not for their interactions (edges). So we calculated the score of the interactions by averaging the scores 
of their associated genes. The score of each interaction shows its relevance to the seed genes. GUILDify score 
varies between 0 and 1, so as the interaction scores. The score close to 1 indicates stronger relevance to a specific 
phenotype.
We merged the two subnetworks i.e. BMSN and LMSN, produced by GUILDify webserver to have a single 
network. This network consisted of 12,172 genes and 324,280 interactions coming from various databases includ-
ing UniProt29, TREMBL37, GO38, OMIM39, Reactome40, INTACT41, MINT42, DIP43, and HPRD44.
Filtering the Network. The examination of the interacting protein pairs and their affinities from experi-
mental methods includes both direct and indirect interactions. As we aimed to use only physical protein inter-
actions, we filtered our data by using experimental protein interactions from STRING database45 with medium 
confidence score to eliminate bulk network clusters and further computational load in 3D protein interaction 
analysis. STRING database collects available experimental information coming from primary interaction data-
bases and assigns confidence score by considering both direct and indirect interactions. Using medium confi-
dence score, we aimed to eliminate the PPIs with lower probability to be physical (or direct) interactions.
Using the STRING database45, we downloaded Human Interaction Network (HIN) consisting of 165,184 pro-
tein interactions. From this network, we only considered protein interactions coming from experimental data 
with the confidence score ≥0.4 (Supplementary Table S2).
After creation of the STRING human interaction network, we compared it with our merged network and 
selected the interactions presented in both networks. After this process, our network diminished to 43,903 inter-
actions and 9,544 genes. Before filtering the network, there were many proteins with extremely high degrees. As 
an example, FSCN1 had 804 neighbours and it had a mesh-like cluster. However, after filtering the network its 
degree decreased to only 18 nodes.
To proceed with structural analysis, we selected the first 1000 interactions having highest GUILDify scores 
from each subnetwork. GULDify scores of edges range between 0.08–0.55 and 0.04–0.58 in BMSN and LMSN 
respectively. There were 95 nodes and 73 edges in common between BMSN and LMSN (Supplementary Fig. S1). 
The merged network contained 1927 interactions as shown in Table 1, where 1240 of them have experimental 
evidence for binding, 497 of these 1240 interactions are physical interactions and 107 of them come from APMS.
We used Cytoscape46 to visualize the subnetworks. Topological and functional analyses of the subnetworks 
can be found in our previous study28.
Results and Discussion
Mapping Protein Conformations to Network. We used UniProt Knowledgebase29 to map the proteins 
to their known 3D structures. We cluster the protein structures corresponding to the same UniProt ID according 
to their sequence identity and structural alignment using the clustering algorithm described in Materials and 
Methods section. Figure 5 shows the clustering statistics of the proteins in our subnetworks. Figure 5a represents 
the number of monomer structures deployed for each protein in the PDB database. As can be seen from the fig-
ure, ~90% of our network’s proteins have at least two available monomer structures in the PDB database. HBA1 
(hemoglobin subunit alpha 1) is the protein with maximum number of available structures in our network with 
439 PDB monomer structures. Figure 5b shows the number of clusters for each protein based on our clustering 
algorithm. As can be seen from the figure, ~50% of the proteins has just one cluster meaning that all their PDB 
structures shows the same conformation of the protein. After clustering, HBA1’s PDB structures grouped in just 3 
different clusters. In this step, APP (amyloid beta precursor protein), with 237 PDB monomer structures, had the 
maximum number of clusters with 61 clusters. As we mentioned earlier, PDB structures of a protein may cover 
different parts of the protein. So, if a protein has 3 clusters based on our clustering algorithm, it does not necessar-
ily mean that it has three alternative conformations in the PDB database as those clusters may represent different 
Network















BMSN 567 1000 262 376 186 254
LMSN 622 1000 280 387 224 322
Merged Network 1094 1927 484 720 390 547
Table 1. Coverages of PDB and PRISM in our subnetworks. aIf proteins at both ends of an edge have PDB 
structures. bIf PRISM has a prediction for that edge.
www.nature.com/scientificreports/
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overlapping/non-overlapping parts of the protein. Two clusters are considered overlapping if they share two or 
more residues. Therefore, to discover the exact number of alternative conformations each protein has, we mined 
the protein clusters, for the proteins having at least two clusters, to find the different PDB structures covering the 
same part of the protein. Figure 5c shows that ~22% of the proteins in our network has at least two alternative 
conformations saved in the PDB database. So, the remaining 28% of proteins having at least two clusters, in fact 
have different regions of proteins saved in PDB database instead of alternative conformations. APP (amyloid pre-
cursor protein) and CALM1 (calmodulin 1) have the maximum number of conformations with nine alternative 
conformations in our network. CALM has 163 PDB monomer structures grouped in 31 clusters.
Figure 6 shows our merged structural network in which node size represents the node degree in the network 
and the colour of nodes correspond to alternative conformations, i.e. the darker the colour is, the more alternative 
conformation it has. As can be seen from the figure, high degree nodes in the network are all light pink except 
CXCR4 (C-X-C chemokine receptor type 4) which is a small structure consisting of a random coil. Although this 
observation may seem counterintuitive, it can be explained as follows: our definition of alternative conformation 
considers large conformational changes for the structures belonging to the same part of a protein, however small 
local conformational changes in proteins’ binding sites may disrupt a specific interaction or promote another 
interaction47.
Modelling 3D Structures of the Binary Protein Interactions. We used PRISM webserver48–50 for 
modelling the binary protein interactions in the structural BMSN and LMSN. PRISM uses a template interface set 
to predict binding sites of two interacting proteins. Its prediction algorithm investigates the surface regions of two 
Figure 5. PDB database and clustering statistics. (a) Number of deployed monomer structures for each protein 
in the PDB database. (b) Number of different clusters for each protein based on our clustering algorithm. These 
clusters may represent different parts of the same protein or alternative conformations of it. (c) Number of the 
alternative conformations each protein has in our network.
www.nature.com/scientificreports/
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proteins and if they are similar to two sides of a crystal or NMR interface structure, it models their complex struc-
ture using that template interface. The rationale of using interfaces instead of whole protein structure for dock-
ing purposes in PRISM is that similar binding sites can be found even in globally different protein structures51. 
PRISM algorithm consists of four steps. In the first step, it extracts the surfaces of target proteins. Then, it splits 
the template interfaces into two sides and using MultiProt52 it calculates the similarity of each template interface 
side to the target protein surfaces in the second step. Multiprot can find the structural similarities of proteins in 
an order-independent manner which is necessary for surface/interface comparisons. After finding two target 
protein surfaces which are similar to two sides of a template interface, and making sure that at least one hotspot 
at each side is conserved, PRISM transforms the surfaces to the template interface to form a protein complex in 
the third step. Finally, in the last step, FiberDock53, 54 is used for flexible refinement of the complexes and ranking 
them based on the binding energy scores. Fiberdock models both backbone and side-chain flexibility. The current 
PRISM webserver uses 22,604 template interfaces which were extracted from binary protein interactions stored 
in the PDB database55.
Not all the proteins in our subnetworks have available 3D structures in the PDB database, so we could not 
model their interactions using the PRISM webserver. As Table 1 shows, only ~44% of the proteins in our network 
have PDB structures. After clustering the protein structures, we investigate all alternative conformations of the 
interacting proteins for each interaction/edge in our network to predict if they can bind to each other and how 
they bind. To do so, we submitted more than 4500 PPIs to PRISM. PRISM webserver modelled ~76% of the 
structural interactions submitted to it (Table 1). To show the effect of using multiple conformations of proteins in 
PPI predictions instead of a single conformation, we randomly selected one conformation for each of the proteins 
in our network and look at their PPI predictions. As shown in Table 1, investigating just one conformation for 
each protein in the network diminished the PRISM predictions by ~22%, so the PRISM coverage of the network 
edges reduced to just ~54%. Therefore, using one conformation for protein docking is not enough and may bring 
incomplete results. All the data are available through http://prism.ccbb.ku.edu.tr/data/fr1.
Equipped with protein structures and their conformations in our network, we show the importance of inves-
tigating protein structures, their conformational changes, and effects of mutations on the protein-protein interac-
tions through the following three case studies.
Conformational Selection Mechanism of KPNB1. KPNB1 (Importin subunit beta-1) is a member of 
Karyopherin family which transports proteins into and out of the nucleus. It has been known that unlike impor-
tin α, members of importin β family can bind to proteins directly and import them independently56. KPNB1 has 
62 interactions in our network in which 41 of its neighbours has 3D structures available in the PDB database as 
shown in Supplementary Fig. S2.
KPNB1 is a protein of length 876 and there is almost complete structure in the PDB database. There are 19 
PDB structures for KPNB1 which are clustered to 7 different clusters based on our algorithm i.e. 3w5kA, 1qgrA, 
3lwwC, 1qgkA, 1ibrB, 2q5dB, and 2qnaA. Figure 7 shows a coarse-grained representation of KPNB1 and its 7 
Figure 6. Merged structural network. Node size shows the node degree. Node colour corresponds to the 
number of alternative conformations, i.e. the darker the node colour is, the more alternative conformation it 
has.
www.nature.com/scientificreports/
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different cluster representatives based on our algorithm. As can be clearly seen from the figure, PDB structures 
1ibrB and 2qnaA cover different parts of KPNB1 so we don’t use them as alternative conformations of KPNB1 in 
our analysis. 3D structures of the five alternative conformations of KPNB1, i.e. 3w5kA, 3lwwC, 1qgkA, 1qgrA, 
and 2q5dB, are shown in Supplementary Fig. S3 and the RMSD values of their aligned structures are shown in 
Supplementary Table S3. These structures show the open and close conformations of KPNB1.
We submitted all possible interactions of KPNB1 with its neighbours using their alternative conformations to 
PRISM. For representation purposes we focus only on 6 different interactions of KPNB1 in our network. Based 
on the PRISM predictions, we reach the structural network shown in Fig. 8.
The complex structures of interactions KPNB1-SNUPN and KPNB1-KPNA2 are already available in the 
PDB database namely PDB ids 3lww and 1qgk, respectively. The close conformation of KPNB1 i.e. 3lwwC is 
bound to SNUPN (Snurportin-1). KPNB1 uses SNUPN adapter to bind cargo molecules to import m3G-capped 
U snRNPs57. SNUPN has an IBB (importin-β-binding) domain in its N-terminal which is used to bind to KPNB1 
and then transport to the nucleus. It has been shown that after each round of import, SNUPN uses CRM1 to 
return back to the cytoplasm58. KPNB1 close conformation 3lwwC bound to SNUPN is represented in Fig. 9a. 
This complex protein structure has the global binding energy of −49.82 based on the Fiberdock webserver53, 54. 
To detect the binding residues in this complex structure we used HotRegion webserver59. The binding residues 
of this complex structure are listed in Supplementary Table S4, and they are indicated with opaque colours in the 
figure. We used UCSF Chimera package60 for molecular graphics and analyses.
Notwithstanding the high RMSD values between open and close conformations of KPNB1, Bhardwaj and 
Cingolani61 provided structural evidence that open and close conformations of KPNB1 bind to SNUPN IBB 
domain. We had the same results in PRISM predictions as shown in Fig. 8. It should be noted that, though 
SNUPN binds to all conformers of KPNB1, it has a different affinity, in terms of binding energy, towards each 
conformer. For example, the predicted binding energy scores for the interaction of SNUPN with 2q5dB and 
1qgkA conformers are −67.38 and −53.32 respectively.
Figure 7. KPNB1 protein and its alternative conformations representative structures after clustering all PDB 
structures of it.
Figure 8. KPNB1’s existing and predicted interactions by PRISM. Interactions having the complex structures in 
PDB database are shown with solid lines. Dotted lines indicate the PRISM predictions.
www.nature.com/scientificreports/
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Another existent interaction of KPNB1 is with KPNA2 (PDB id 1qgk). KPNA2 (Importin subunit alpha-
1) is an adapter protein for KPNB1 which binds to substrates containing a nuclear localization signal (NLS) 
motif. Importin β binds to the IBB domain of importin α and forms a heterodimer. Cytosolic proteins having 
NLS-containing motifs form a complex with this heterodimer and transported into the nucleus by using nuclear 
pore complexes (NPCs) which are embedded on the nuclear membrane62, 63. The available PDB complex structure 
for KPNB1-KPNA2 uses a KPNB1 close conformer as shown in Fig. 9b. The binding residues of this complex 
structure are listed in Supplementary Table S5, and they are indicated with opaque colours in the figure. There 
are 17 residues in common between KPNB1 interacting surface with SNUPN and KPNA2 based on HotRegion 
webserver59 shown with boldface in Supplementary Tables S4 and S5 which indicates that KPNB1 uses almost the 
same region to bind to these proteins. This complex protein structure has the global binding energy of −138.40 
based on the Fiberdock webserver. However, based on the PRISM results, KPNA2 can bind to other conformers 
of KPNB1 though with significantly fluctuating binding energies e.g. −78.25 and −22.32 to bind to 1qgrA and 
3lwwC respectively.
Liang et al.64 showed that KPNA2/KPNB1 canonical pathway is responsible for p65 (RELA proto-oncogene, 
NF-kB subunit) import to the nucleus. They tested 6 different members of the importin α family and found that 
KPNA2 plays the major role in p65 import. p65 uses different members of importin β and α families for its import 
but it has a high affinity towards KPNB1 and KPNA2. Based on their results, p65 hetero trimer is imported to the 
nucleus through Nuclear Pore Complexes (NPCs). The proteins involved in this pathway are connected to each 
other in our network, in the order RELA-KPNA2-KPNB1-NUP153. Figure 10 shows this pathway in which the 
interaction KPNB1-KPNA2 is represented with its structural details. Despite the large conformational changes of 
KPNB1, its binding site to KPNA2 remains almost intact enabling it to bind to KPNA2 in different conformations. 
Figure 9. KPNB1 complex structures with. (a) SNUPN (PDB ID 3lwwCD) (b) KPNA2 (1qgkAB), and (c) 
SNAI1 (3w5kAB). The binding residues on the surface are indicated as opaque.
Figure 10. Pathway for p65 import based on Liang et al.64.
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It is important to know that using which alternative conformations, the proteins involved in a pathway can bind 
to each other and pass the signal.
By looking at the PDB database, we found that there are other complexes for KPNB1 which complex with 
RAN, SNAI1, and PTHLH. Among all available structures of KPNB1, only 3w5kA is bound to the zinc finger pro-
tein SNAI1. SNAI1 is a transcription factor which has been found in a number of carcinomas and melanomas65. 
Its expression in breast carcinoma is associated with tumour growth and metastasis66–68. Besides, in vivo experi-
ments showed that silencing of SNAI1 significantly diminishes tumour occurrence and growth69.
We would like to know if other conformers of KPNB1 can bind to SNAI1 too, so we submit all other alterna-
tive conformations of KPNB1 with SNAI1 to the PRISM webserver. Interestingly, PRISM can only find the com-
plex structure using 2q5dB conformer of KPNB1 for these submissions. In this complex, SNAI1 binds to 2q5dB 
from the same binding site it uses to interact with 3w5kA. The binding energy score for this complex is −139.17, 
and the binding residues are listed in Supplementary Data 26. Therefore, KPNB1 conformers 3w5kA and 2q5dB 
can bind to SNAI1 and import it into the nucleus. KPNB1 open conformation 3w5kA bound to SNAI1 is shown 
in Fig. 9c. The binding residues of this complex are listed in Supplementary Table S6, and they are indicated with 
opaque colours in the figure. There are 19 residues in common between KPNB1 interacting surface with SNAI1 
and KPNA2 based on Hotregion webserver59 shown with italic typeface in Supplementary Tables S5 and S6 which 
indicates that KPNB1 uses almost the same region to bind to these proteins.
These evidences lead us to infer that some protein conformers are more limited in terms of their binding part-
ners’ quantities e.g. KPNB1 can bind to SNUPN or SNAI1 in open conformation though it can’t bind to SNAI1 
in close conformation. Therefore, each specific protein conformer put a limitation on the diversity of possible 
binding partners.
Conformational Changes of CXCL12 Leading to Different Downstream Signalling. CXCL12 
(C-X-C motif chemokine 12) is the ligand of CXCR4 (C-X-C chemokine receptor type 4) which is a seed gene 
in LMSN. This interaction has GUILDify score of ~0.5 which places it in the top 5% interactions in LMSN. It is 
known that in-vivo inhibition of these two genes reduce breast cancer metastasis progress of lung70. Chemokines 
are small proinflammatory chemoattractant cytokines which bind to specific G-protein-coupled receptors. 
CXCL12 is expressed in several organs including lung, liver, brain, skeletal muscle, kidney, heart, skin, and bone 
marrow. The binding of CXCL12 to CXCR4 is known to induce intracellular signalling through several different 
pathways initiating signals related to chemotaxis, cell survival and/or proliferation71.
The CXCL12-CXCR4 interaction is involved in tumour progression, angiogenesis, metastasis, and survival. 
There are efforts to block metastatic dissemination by inhibiting CXCR4 activation72 to inhibit cancer malig-
nancy73, 74. It has been shown that binding to CXCR4 N terminus (CXCR4 1–38) promotes CXCL12 dimerization75. 
Drury et al.76 found that oligomeric changes of CXCL12 induces cellular migration with monomer but not 
dimer77. Interestingly, they also observed that dimeric CXCL12 exhibited receptor interactions and downstream 
signalling different from the monomeric chemokine. Their results show that monomeric CXCL12 activates 
β-arrestin-2 recruitment and filamentous-actin accumulation. On the other hand, dimeric CXCL12 weakly 
recruits β-arrestin-2 and diminishes actin polymerization compared to monomeric CXCL1278. This indicates that 
monomeric and dimeric CXCL12 can have different outcomes in metastasis phenotypes upon CXCR4 binding.
Different signalling outcomes might be related to alternative conformations of CXCL12 upon CXCR4 bind-
ing. There are 20 available structures in PDB database for CXCL12 which are divided to 11 clusters based on our 
clustering method. It is known that conformational changes can be related to point mutations on the protein 
interfaces which may change their dimerization profile and structural arrangement. There are several mutations 
known on the CXCL12 protein. One important mutation is H25R substitution at the binding interface which 
discourages CXCL12 dimerization, thus it is preferentially monomeric76, 79. However, some studies have also 
reported that binding of the CXCR4 N-terminus (CXCR4NT) induces H25R mutated CXCL12 (CXCL12H25R) 
dimerization80. Here we investigate the homodimerization of CXCL12WT and CXCL12H25R, and the interaction 
of CXCL12 with CXCR4N-terminus by using PRISM to better understand the conformational differences and their 
downstream effects. Figure 11a shows the pairwise superposition of CXCL12WT (PDB ID: 2j7zA) conformation 
Figure 11. CXCL12 monomer and dimer structures. (a) Superposition of CXCL12WT (PDB ID: 2j7zA) and 
CXL12H25R (PDB ID: 2kolA) conformations. The RMSD value of aligned structures is 6.29 Å. (b) Superposition 
of the PRISM prediction for CXCL12WT homodimer (orange) and the available structure in PDB i.e. 2j7z (blue). 
(c) PRISM prediction for CXCL12H25R homodimer.
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and its H25R mutated conformation (PDB ID: 2kolA). As can be seen from the figure they don’t align perfectly on 
top of each other, especially in N- and C-terminal parts. Besides, there is a significant difference in their surfaces 
at residue 25 as shown in Fig. 11a. Based on our clustering method, these two conformations belong to different 
clusters.
The PRISM webserver predicted the homodimer formation for both CXCL12WT, and CXCL12H25R. However, 
in case of the CXCL12H25R the binding energy diminished significantly as expected. The binding energy score for 
CXCL12WT homodimer is −101.41, while it is −17.24 for CXCL12H25R homodimer. The binding residues of these 
homodimer structures are listed in Supplementary Table S7. Figure 11b shows the superposition of the PRISM 
prediction for CXCL12WT homodimer and the available structure in PDB database. There is no structure in PDB 
database for CXCL12H25R homodimer to compare with the PRISM prediction shown in Fig. 11c.
Afterwards we looked at the binding of monomeric CXCL12 variants to CXCR4NT. For both interactions, 
CXCL12WT-CXCR4NT and CXCL12H25R-CXCR4NT, the PRISM has predictions with acceptable binding ener-
gies of −87.25 and −52.48 respectively. Tyrosine sulfation is known to promote the protein−protein interac-
tions. There are three potential sulfation sites on CXCR4NT at positions 7, 12, and 2180 which PRISM used two of 
them in its predictions (Supplementary Table S8). Figure 12a and b show the PRISM predictions for interactions 
CXCL12H25R-CXCR4NT and CXCL12WT-CXCR4NT respectively, in which CXCR4 surrounded CXCL12.
Based on these results we can conclude that CXCL12 binds to CXCR4NT in wildtype and mutated forms. 
As monomeric CXCL12–CXCR4NT interaction is said to stimulate the dimerization of CXCL12, we predicted 
interaction of CXCL12WT:CXCR4NT heterodimer to CXCL12WT, and CXCL12H25R:CXCR4NT heterodimer to 
CXCL12H25R. Interestingly, the PRISM could only find interaction for CXCL12WT:CXCR4NT heterodimer to 
CXCL12WT with the binding energy of −85.31 and could not predict a binding for CXCL12H25R:CXCR4NT het-
erodimer to CXCL12H25R. This shows that binding of CXCR4NT to CXCL12H25R cannot induce homo-dimerization 
of CXCL12H25R as it may partly occupy the dimerization interface of CXCL12H25R. Therefore, a single point 
mutation can inhibit CXCL12 dimerization which can contribute to metastatic profile and tumour dissem-
ination. Fig. 12c shows the PRISM prediction for the trimer structure of CXCL12WT:CXCR4NT-CXCL12WT. 
Supplementary Fig. S4 and Table S9 show the superposition of this predicted complex with available dimer struc-
ture of CXCL12WT, and list of the binding residues of this complex structure respectively.
Consequently, as proteins are dynamic and changing conformations based on environmental factors, they 
favour different binding partners at each time point. Therefore, investigating alternative conformations for each 
protein is vital in structural PPI networks to have a precise understanding of protein interactions and signalling 
pathways.
We submitted all the interactions for these two case studies to Zdock81, GRAMM-X82, and PatchDock83, 84 web-
servers too. The common residues between their predictions and PRISM predictions are listed in Supplementary 
Tables 10 and 11.
Mutual Exclusive Interactions of NEDD9 with SMAD3 and NCK1. NEDD9 (neural precursor cell 
expressed, developmentally down regulated 9), SMAD3 (SMAD family member 3), and NCK1 (NCK adaptor 
protein 1) complex is an example of mutually exclusive interactions in LMSN. NEDD9 is a scaffolding protein, 
and it was previously identified as the lung metastasis causing gene in breast cancer35. It was used as a seed gene 
in LMSN creation and previously identified as metastatic hub protein in cancer signalling85. Figure 13 shows 
NEDD9 cluster i.e. its first neighbours in LMSN. NEDD9 is associated with many cellular processes such as cell 
adhesion, migration, proliferation, apoptosis and homeostasis86. The major role of NEDD9 is to promote assem-
bly of proteins in order to maintain these cellular processes through cell signalling.
Both N-terminal and C-terminal sequences of NEDD9 are known to bind to SMAD3 causing rapid turno-
ver of NEDD987, 88. It has been found that the residues 301–330 of SMAD3 (PDB ID: 1MK2), which forms the 
MH2 domain, are more important for binding to NEDD987. NEDD9 has only one structure available in PDB 
Figure 12. PRISM predictions for (a) CXCL12H25R (orange)-CXCR4NT (blue) interaction, (b) CXCL12WT 
(pink)-CXCR4NT (blue) interaction, and (c) CXCL12WT:CXCR4NT(pink:blue)-CXCL12WT (green) trimer 
structure. Binding residues are indicated as opaque.
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which covers residues 399–563 (PDB ID: 2L81) presenting a serine-rich four helix bundle domain. As shown in 
Fig. 13, the PRISM webserver predicted that NEDD9 binds to SMAD3 MH2 domain with binding energy score 
of −34.29.
On the other hand, PRISM predictions suggest that NEDD9 binds to NCK1 from the same region it binds to 
SMAD3 (Fig. 13). The binding energy score of the prediction is −22.46. NCK1 is cytoplasmic non-catalytic region 
of tyrosine kinase adaptor protein which facilitates the construction of larger protein assemblies. NCK1 has both 
SH2 and SH3 domains in its structure89. Previously, it was identified that NCK1 binds to NEDD9 by using its 
SH2 domain90. We observed the same result in the PRISM predictions. The predicted interface of NEDD9-NCK1 
interaction consists of 26 residues and NEDD9-SMAD3 interaction interface consists of 33 residues. There are 7 
residues in common between these interfaces (Supplementary Table S12).
Based on these results, NEDD9-SMAD3 and NEDD9-NCK1 interactions are mutually exclusive so we cannot 
see these two edges at the same time in the PPI network. Thus, to achieve to the actual topology of a PPI network 
we need to inspect the structural aspects of proteins. By considering the mutual exclusive interactions, the degree 
of NEDD9 in LMSN at any specific time point may decrease significantly.
Conclusions
The main objective of this study is to emphasize the importance of investigating alternative conformations of 
proteins in structural PPI networks to be able to analyse the protein interactions more accurately. This informa-
tion enables us to observe the effects of conformational changes, mutations, and mutual exclusiveness on specific 
protein interactions and downstream signalling.
To this end, we have built extensive protein-protein interaction network for breast cancer lung and brain 
metastasis by combining various databases. Then, we ranked all available interactions according to their relevance 
to specific breast cancer metastasis phenotypes. Using the STRING database, we filtered our network to increase 
the reliability of the protein interactions. To map the protein structures into the network, we proposed a clustering 
algorithm based on sequence and structural similarity of protein structures to prevent repetition in our analyses.
We used PRISM to model the 3D structures of the PPIs in our networks. However, we could not predict the 
whole interactions in our metastasis subnetworks since not all of the proteins have structures stored in the PDB 
database. By using alternative conformations of proteins in our subnetworks, we observed the effects of protein 
conformational changes on protein interactions and downstream signalling. We inspected the conformational 
changes of KPNB1 which directs it to bind to SNAI1 in the open conformation and bind to SNUPN in the open/
Figure 13. NEDD9 cluster in LMSN and PRISM predictions for its interactions with NEDD9 and SMAD3. 
(Top) Colour of the edges corresponds to PDB and PRISM coverages. Blue edges are covered by PDB, and green 
edges are covered by PRISM. (Bottom) Binding residues are indicated with opaque colours in each complex 
protein structure.
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close conformation. It shows the limitations posed by the conformational changes of proteins which fluctuates 
their ability to stablish various interactions. This is an example of conformational change effects exist in the PDB 
database. As another case study, we examined the interactions CXCL12WT-CXCR4NT and CXCL12H25R-CXCR4NT. 
Based on our results, CXCL12H25R and CXCL12WT can bind to CXCR4NT, and this interaction has been shown to 
direct the migration of metastatic breast cancer cells to specific tissues. However, binding to CXCR4NT inhibits 
CXCL12H25R dimerization which is not the case for CXCL12WT. Dimerization of CXCL12 as the ligand of CXCR4 
is important as it stimulates intracellular calcium flux but fails to activate F-actin polymerization or β-arrestin 2 
recruitment which has been shown to cause cellular idling that blocks the metastatic tumour formation.
Investigating the structural models, we detected the mutual exclusive interactions. As a case study, we looked 
at NEDD9 mutually exclusive interaction partners. PRISM predicted that NEDD9-SMAD3 and NEDD9-NCK1 
interactions are mutually exclusive. This difference can cause activation of different pathways which lead to differ-
ent metastasis phenotypes. It is known that NEDD9-SMAD3 interaction causes proteolytic cleavage of NEDD9 
which induces cell detachment, apoptosis and individual motility of metastasis cells. However, exact role of 
NCK1-NEDD9 binding was not previously examined in detail.
Overall, we created the brain and lung metastasis subnetworks of breast cancer and modelled the 3D struc-
tures of the protein-protein interactions to describe the significance of protein structural data and conformational 
changes through the several case studies. We believe that this study may be beneficial to appreciate the inability of 
traditional PPI networks, which lack structural and dynamics information of proteins, to provide a detailed view 
of protein interactions and their functions.
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